Zdrowie i gospodarka · 28/10/1996
FDA Proposes to Revise Postmarketing Adverse Experience Reporting Regulations
The FDA is proposing to simplify postmarketing reporting of adverse experiences for human drugs and licensed biological products by eliminating the requirement for increased frequency reports, which the agency believes are no longer necessary for identifying safety problems.